Study: NCT00980330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.